Success Metrics

Completion Rate

0%(0/2)

Active Trials

1(25%)

Terminated

2(50%)

Phase Distribution

Ph early_phase_1

25%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 1Safety & dosage

3(75.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Terminated(2)

Other(1)

Detailed Status

Terminated2

Recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 1

Trials by Phase

Early Phase 11 (25.0%)

Phase 13 (75.0%)

Trials by Status

recruiting125%

terminated250%

unknown125%

Recent Activity

1 active trials

Showing 4 of 4

recruitingphase_1

GT201 Injection For The Treatment Of Advanced Solid Tumors

NCT06144671

terminatedphase_1

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors

NCT05430360

terminatedphase_1

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

NCT05729399

unknownearly_phase_1

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

NCT05724732

Clinical Trials (4)

Showing 4 of 4 trials

NCT06144671Phase 1

GT201 Injection For The Treatment Of Advanced Solid Tumors

Recruiting

NCT05430360Phase 1

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Terminated

NCT05729399Phase 1

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Terminated

NCT05724732Early Phase 1

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

Unknown

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4